Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Apellis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1—Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |||||||||
| Newly Registered Securities | ||||||||||||||||
| Fees to be Paid |
Equity | Common Stock, par value $0.0001 per share | 457(o) and (r) | (1) | (1) | $300,000,000(1) | 0.00014760 | $44,280.00 | ||||||||
| Fees Previously Paid |
— | — | — | — | — | — | — | — | ||||||||
| Carry Forward Securities | ||||||||||||||||
| Carry Forward Securities |
— | — | — | — | — | — | — | — | ||||||||
| Total Offering Amounts | $300,000,000 | — | $44,280.00 | |||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||
| Total Fee Offsets | — | |||||||||||||||
| Net Fee Due | $44,280.00 | |||||||||||||||
| (1) | The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”), based on the proposed maximum aggregate offering price, and Rule 457(r) under the Securities Act. In accordance with Rules 465(b) and 457(r) under the Securities Act, the registrant initially deferred payment of all of the registration fee with respect to an indeterminate amount of the registrant’s common stock registered under the Registration Statement on Form S-3 (File No. 333-269899) filed with the Securities and Exchange Commission on February 22, 2023. |